Skip to content

Lag of Accommodation With DOT Spectacle Lenses

Lag of Accommodation With DOT Spectacle Lenses

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04700111
Acronym
ASH
Enrollment
30
Registered
2021-01-07
Start date
2022-02-01
Completion date
2026-12-31
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast

Brief summary

The objective of the study is to measure the difference in the lag of accommodation between DOT spectacle lenses and control spectacles.

Interventions

DEVICEDOT Pattern

DOT Pattern Spectacle Lens

DEVICEControl Spectacles

Control lens

Sponsors

SightGlass Vision, Inc.
Lead SponsorINDUSTRY
University of Waterloo
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
6 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

A person is eligible for inclusion in the study if he/she: 1. Age 6-18 years of age, with a maximum of 6 of the first 25 completed participants being older than 14 years of age. 2. Is able to read (or be read to), understand and sign the assent document if under 17 years old or is able to read, understand and sign the consent document if aged 17 or 18 years. 3. Is under 17 years old and is accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document. 4. Should be emmetropic by non-cycloplegic auto-refraction, which means both refractive meridians should be within +1.00D and -1.00D. 5. Is willing and able to follow instructions. A person will be excluded from the study if he/she: 1. Is participating in any concurrent clinical or research study. 2. Have a history of myopia control treatment in the past year. 3. Has amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency. 4. Has any known active ocular disease and/or infection. 5. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism. 6. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include Atropine eye drops. 7. Has undergone strabismus surgery, refractive error surgery or intraocular surgery. 8. Is a child of a member of the study team.

Design outcomes

Primary

MeasureTime frameDescription
Best vision sphere90 minutes1\) Autorefractor spherical equivalent refraction measured at distance and at 40cm with each pair of treatment spectacles

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026